Pharsight

Drugs that contain Mipomersen Sodium

1. Kynamro patents expiration

KYNAMRO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7015315 KASTLE THERAPS LLC Gapped oligonucleotides
Mar, 2023

(1 year, 8 days ago)

US7101993 KASTLE THERAPS LLC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(6 months ago)

US7511131 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Jan, 2027

(2 years from now)

Market Authorisation Date: 29 January, 2013

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

KYNAMRO family patents

Family Patents